Endogenous leukemia inhibitory factor attenuates endotoxin response

Laboratory Investigation

Volumn 85, Issue 2, 2005, Pages 276-284

  Weber, Marietta A ^a   Schnyder Candrian, Silvia ^b   Schnyder, Bruno ^b   Quesniaux, Valerie ^b   Poli, Valeria ^c   Stewart, Colin L ^b   Ryffel, Bernhard ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CNRS   (France)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Endotoxic shock; IL 6, acute phase; LIF; LIF deficient mice; LPS; TNF

Indexed keywords

ENDOTOXIN; GALACTOSAMINE; INTERLEUKIN 10; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HOST RESISTANCE; INFLAMMATION; LEUKOPENIA; LIVER NECROSIS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SEPTIC SHOCK; THROMBOCYTOPENIA;

ACUTE-PHASE REACTION; ANIMALS; CELLS, CULTURED; DOWN-REGULATION; ENDOTOXEMIA; ENDOTOXINS; GALACTOSAMINE; INTERLEUKIN-10; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; LIPOPOLYSACCHARIDES; LIVER; LUNG; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RNA, MESSENGER; SERUM AMYLOID A PROTEIN; SHOCK, SEPTIC; SPLEEN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 13444269092     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700216     Document Type: Article

References (43)

1. Metcalf D. The leukemia inhibitory factor (LIF). Int J Cell Cloning 1991;9:95-108.
2. Hilton DJ. LIF: lots of interesting functions. Trends Biochem Sci 1992;17:72-76.
3. Chesnokova V, Melmed S. Minireview: neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology 2002;143:1571-1574.
4. Alexander HR, Billingsley KG, Block MI, et al. D-factor/ leukaemia inhibitory factor: evidence for its role as a mediator in acute and chronic inflammatory disease. Cytokine 1994;6:589-596.
5. Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20.
6. Gadient RA, Patterson PH. Leukemia inhibitory factor, interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells 1999;17:127-137.
7. Gough NM, Williams RL, Hilton DJ, et al. LIF: a molecule with divergent actions on myeloid leukaemic cells and embryonic stem cells. Reprod Fertil Dev 1989;1:281-288.
8. Waring P, Wycherley K, Cary D, et al. Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids. J Clin Invest 1992;90:2031-2037.
9. Waring PM, Waring LJ, Metcalf D. Circulating leukemia inhibitory factor levels correlate with disease severity in meningococcemia. J Infect Dis 1994;170:1224-1228.
10. Block MI, Fraker DL, Strassmann G, et al. Endogenous D-factor activity partially mediates the toxic but not the therapeutic effects of tumor necrosis factor. Int J Cancer 1995;63:245-249.
11. Waring PM, Waring LJ, Billington T, et al. Leukemia inhibitory factor protects against experimental lethal Escherichia coli septic shock in mice. Proc Natl Acad Sci USA 1995;92:1337-1341.
12. Alexander HR, Wong GG, Doherty GM, et al. Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with interleukin 1 and tumor necrosis factor. J Exp Med 1992;175:1139-1142.
13. Ulich TR, Fann MJ, Patterson PH, et al. Intratracheal injection of LPS and cytokines. V. LPS induces expression of LIF and LIF inhibits acute inflammation. Am J Physiol 1994;267:L442-L446.
14. Zhu M, Oishi K, Lee SC, et al. Studies using leukemia inhibitory factor (LIF) knockout mice and a LIF adenoviral vector demonstrate a key anti-inflammatory role for this cytokine in cutaneous inflammation. J Immunol 2001;166:2049-2054.
15. Block MI, Berg M, McNamara MJ, et al. Passive immunization of mice against Dfactor blocks lethality and cytokine release during endotoxemia. J Exp Med 1993;178:1085-1090.
16. Stewart CL, Cullinan E. LIF and related cytokines in the regulation of mammalian development. Ann NY Acad Sci 1995;762:29-30.
17. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979;76:5939-5943.
18. Alcorn JM, Fierer J, Chojkier M. The acute-phase response protects mice from D-galactosamine sensitization to endotoxin and tumor necrosis factor-alpha. Hepatology 1992;15:122-129.
19. Car BD, Eng VM, Schnyder B, et al. Interferon gamma receptor deficient mice are resistant to endotoxic shock. J Exp Med 1994;179:1437-1444.
20. Escary JL, Perreau J, Dumenil D, et al. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 1993;363:361-364.
21. Muller M, Eugster HP, Le Hir M, et al. Correction or transfer of immunodeficiency due to TNF-LT alpha deletion by bone marrow transplantation. Mol Med 1996;2:247-255.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 1987;162:156-159.
23. Keppler D, Lesch R, Reutter W, et al. Experimental hepatitis induced by D-galactosamine. Exp Mol Pathol 1968;9:279-290.
24. Marchant A, Bruyns C, Vandenabeele P, et al. The protective role of interleukin-10 in endotoxin shock. Prog Clin Biol Res 1994;388:417-423.
25. Shakhov AN, Woerly G, Car BD, et al. Interferon-gamma enhances tumor necrosis factor-alpha production by inhibiting early phase interleukin-10 transcription. Eur Cytokine Netw 1996;7:741-750.
26. Marchant A, Deviere J, Byl B, et al. Interleukin-10 production during septicaemia. Lancet 1994;343:707-708.
27. Marchant A, Bruyns C, Vandenabeele P, et al. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994;24:1167-1171.
28. Chesnokova V, Kariagina A, Melmed S. Opposing effects of pituitary leukemia inhibitory factor and SOCS-3 on the ACTH axis response to inflammation. Am J Physiol Endocrinol Metab 2002;282:E1110-E1118.
29. Lehmann V, Freudenberg MA, Galanos C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine- treated mice. J Exp Med 1987;165:657-663.
30. Tiegs G, Wolter M, Wendel A. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 1989;38:627-631.
31. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994;370:218-220.
32. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-871.
33. Pfeffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-467.
34. Libert C, Brouckaert P, Fiers W. Protection by alpha 1-acid glycoprotein against tumor necrosis factor-induced lethality. J Exp Med 1994;180:1571-1575.
35. Sheppard BC, Fraker DL, Norton JA. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery 1989;106:156-161; discussion 161-152.
36. Alexander HR, Doherty GM, Fraker DL, et al. Human recombinant interleukin-1 alpha protection against the lethality of endotoxin and experimental sepsis in mice. J Surg Res 1991;50:421-424.
37. Vogels MT, Cantoni L, Carelli M, et al. Role of acute-phase proteins in interleukin-1-induced nonspecific resistance to bacterial infections in mice. Antimicrob Agents Chemother 1993;37:2527-2533.
38. Barton BE, Jackson JV. Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 1993;61:1496-1499.
39. Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989;143:3517-3523.
40. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101:311-320.
41. Fattori E, Cappelletti M, Costa P, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994;180:1243-1250.
42. Quezado ZM, Hoffman WD, Winkelstein JA, et al. The third component of complement protects against Escherichia coli endotoxin-induced shock and multiple organ failure. J Exp Med 1994;179:569-578.
43. Niehorster M, Tiegs G, Schade UF, et al. In vivo evidence for protease-catalysed mechanism providing bioactive tumor necrosis factor alpha. Biochem Pharmacol 1990;40:1601-1603.